FDA Grants Venetoclax Full Approval for CLL, Regardless of 17p Deletion
The FDA has granted a regular approval to venetoclax for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma , with or without 17p deletion, following at least 1 prior therapy The BCL-2 inhibitor is now also approved for use in combination with rituximab in the same patient population.
Source: OncLive